A phase 1 study of oral ridaforolimus in pediatric patients with advanced solid tumors

PURPOSE: Ridaforolimus is an investigational, potent, selective mTOR inhibitor. This study was conducted to determine the recommended phase 2 dose (RP2D), maximum tolerated dose, safety, pharmacokinetics, and antitumor activity of oral ridaforolimus in children with advanced solid tumors. EXPERIMENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Pearson, Andrew D.J., Federico, Sara M., Aerts, Isabelle, Hargrave, Darren R., DuBois, Steven G., Iannone, Robert, Geschwindt, Ryan D., Wang, Ruixue, Haluska, Frank G., Trippett, Tanya M., Geoerger, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356695/
https://www.ncbi.nlm.nih.gov/pubmed/27713169
http://dx.doi.org/10.18632/oncotarget.12450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356695/
https://www.ncbi.nlm.nih.gov/pubmed/27713169
http://dx.doi.org/10.18632/oncotarget.12450

Ejemplares similares